| | | Re: IONS
An article in Science, the weekly journal of the AAAS, dated March 17, details progress in understanding "Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies," with three of 24 authors listed as IONS employees, including C. Frank Bennett, Exec. VP and Chief Scientific Officer.
"Loss of nuclear TDP-43," according to the article abstract, "is a hallmark of neurodegeneration in TDP-43 proteinopathies, including amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease), frontotemporal dementia (FTD)." It also appears to be a factor in Alzheimer's Disease. Ionis has one ALS drug already approved, another in phase 3, and an Alzheimer's drug in phase 2.
Has Ionis discovered the holy grail?
Art |
|
